Blogs

May 9, 2026
Hero with Title the Affect Heuristic a 2x2 Matrix Left Column Gray Blocks Labeled lucky top and confused bottom Right Column Green disciplined Investor and Orange bias trapped

The Affect Heuristic: Slovic et al.’s 2002 Cognitive Shortcut Behind India’s ₹1.81 Lakh Crore F&O Loss Numbers

Slovic, Finucane, Peters and MacGregor's 2002 Affect Heuristic — feel first, justify second — explains the silent operating system behind Indian retail flows, F&O losses and festival SIP spikes. A counter-measure checklist, a Graham/Buffett/Munger/Klarman lineage, and a positive corporate case-study using Titan Biotech FY25 audited numbers.
May 9, 2026
Bar Chart of Sales to gross block Ratio by Fiscal Year fy20fy25 Values Drop from 28 to 11 Fy25 Bar is Green

Sales-to-Gross-Block Ratio: The Asset Productivity Test

Learn how to read a company's Sales-to-Gross-Block ratio in 60 seconds — the asset-productivity test that separates capital-light compounders from capital-heavy laggards. Titan Biotech FY25's ~3.76x reading is the positive illustration.
May 8, 2026
Dark Blue Hero with the Title the Framing Effect Subtitle tversky  Kahnemans 1981 asian Disease Problem and a 2x2 Color Grid Labeled Lucky Disciplined Investor Confused Bias trapped

The Framing Effect: Tversky & Kahneman’s 1981 ‘Asian Disease Problem’

Tversky & Kahneman's 1981 Asian Disease Problem proved that human preferences reverse under arithmetically identical framings. Indian retail data confirms the effect at industrial scale. Titan Biotech (BSE: 524717) FY25 disclosures publish nearly every material fact in two frames simultaneously — a corporate analogue of the dual-frame discipline the great investors have used for ninety years.
May 8, 2026
Dark Blue Page with the Title export Revenue Mix and a Horizontal Bar Chart of Fiscal Years Fy20fy25 Values Are 28 26 22 18 14 11 with Fy25 Shown in Green

Export Revenue Mix: The Geographic Diversification Test for Indian Small-Caps

Export Revenue Mix isn't just a percentage — it's a forensic test for customer concentration, currency hedging, and pricing power against global benchmarks. Using Titan Biotech FY25's audited ~34.5% export share across 60+ countries as an educational illustration of disciplined geographic diversification.
+91-8448836436